HC Wainwright reaffirmed their buy rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $300.00 price target on the biotechnology company’s stock. Other equities research analysts have also issued reports about the stock. Mizuho lowered their target price on shares of Biogen […]